Anavex Life Sciences Corp. (AVXL) vs Cue Biopharma, Inc. (CUE)

A side-by-side comparison of Anavex Life Sciences Corp. and Cue Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — AVXL vs CUE

growth of $100 · dividends reinvested · last 9y
AVXL -47.8% (-7.0%/yr)CUE -93.0% (-25.6%/yr)AVXL compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020182020202220242026$52$7
AVXL CUE

AVXL vs CUE: by the numbers

  • •CUE is the larger company ($173M vs $152M market cap).
  • •Both run net losses; AVXL's is the smaller (0.00% vs -435.83% net margin).

Metrics side by side

Valuation

MetricAVXLCUE
P/S ratioN/A4.59
P/B ratio1.3574.78

Profitability

MetricAVXLCUE
Gross margin0.00%99.69%
Operating margin0.00%-96.56%
Net margin0.00%-435.83%
ROE-21.38%-7104.24%
ROIC-27.25%-1039.56%

Growth (annualized)

MetricAVXLCUE
Revenue CAGR (5Y)N/A47.08%
Total return CAGR (5Y)-37.74%-42.42%

Frequently asked

How have AVXL and CUE total returns compared?
Over the past 5 years, AVXL delivered -37.74% and CUE delivered -42.42% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.